Ano Kaisha no Shikumi
Search
Menu

Nxera Pharma

Nxera Pharma Co., Ltd.

Company highlights

The largest holder on the register is 日本マスタートラスト信託銀行株式会社(信託口), at 9.4%.

Key figures

Period Jan 2025 to Dec 2025ConsolidatedIFRS

RevenueDisclosed ¥29.6B
Operating marginCalculated -28.6%
Net assets to total assetsCalculated 45.3%

Company profile

Securities code 4565 / EDINET code E00981 / Pharmaceuticals / Fiscal year end December 31

港区赤坂９－７－２／Capital stock ¥47,450 million
Address, capital stock, fiscal year end and industry: the FSA’s EDINET code list.

Company details
CEO クリストファー・カーギル Representative

Tables scroll sideways

Disclosed data

Source: Annual Securities Report (Jan 2025 to Dec 2025) · filed 2026-03-25

Profitability ★☆☆☆☆position among all companies -28.6%
Growth (revenue, 4-year average) ★★★★★position among all companies 13.7%
Capital efficiency ★☆☆☆☆position among all companies -19.3%

Business activities and revenue composition

Revenue and profit by business segment

Disclosed segments (business divisions used in reporting): one

Revenue and profit

Amounts by account
GroupAccountAmountConsolidated / Non-consolidated
Selling, general and administrative expenses Selling general and administrative expenses IFRS ¥15.2 billion Consolidated
General and administrative expenses ¥9.6 billion Parent only
Personnel expenses ¥6.2 billion Consolidated
Depreciation ¥3.5 billion Consolidated
Other ¥2.7 billion Consolidated
Business consignment expenses ¥2.5 billion Consolidated
Profit by stage Net income ¥-12.5 billion Consolidated
Gross profit (loss) ¥12.2 billion Parent only
Operating income ¥-8.5 billion Consolidated
Ordinary income ¥0.7 billion Parent only

Nxera Pharma

Selling, general and administrative expenses

Period Jan 2025 to Dec 2025Source Annual securities reports

Selling general and administrative expenses IFRS ¥15.2 billion (38.4%)38%General and administrative expenses ¥9.6 billion (24.2%)24%Personnel expenses ¥6.2 billion (15.7%)16%Depreciation ¥3.5 billion (8.7%)9%Other ¥2.7 billion (6.8%)7%Business consignment expenses ¥2.5 billion (6.2%)6%¥39.7B
  • Selling general and administrative expenses IFRS　¥15.2 billion
  • General and administrative expenses　¥9.6 billion
  • Personnel expenses　¥6.2 billion
  • Depreciation　¥3.5 billion
  • Other　¥2.7 billion
  • Business consignment expenses　¥2.5 billion

Performance, financial position and capital allocation

Finance
45.3% Net assets to total assets Industry median 69.7% FY ending 12/2025 · consolidated / calculated
-9.3% Return on assets (ROA)
¥493.98 Net assets per share
¥2.8 billion Free cash flow
¥134.8 billion Total assets
¥25.8 billion Goodwill (the part of the acquisition price above the net assets acquired)
Capital allocation
11.8% Increase in working capital ★★★★★ position among all companies FY ending 12/2025 · consolidated / calculated
10.3% Property, plant and equipment purchases relative to depreciation ★☆☆☆☆ position among all companies FY ending 12/2025 · consolidated / calculated

Long-term changes in performance

Period 2013 to 2025Disclosed

Revenue ×15.13 from 2013 to 2025

Nxera Pharma

Long-term revenue, profit and asset trends

Period 2013 to 2025Source Annual securities reportsDisclosed

Mark on the chart
30 15 -0 -15 2013 2015 2017 2019 2021 2023 2025 Net sales and operating revenue Profit before tax 2014　Ordinary income (loss) as a share of revenue -11.2 points 2015　Revenue (IFRS) year on year +77.4% 2017　Revenue (IFRS) year on year -63.2%, Profit (loss) before tax (IFRS) as a share of revenue -119.3 points, Profit (loss) before tax (IFRS) profit to loss 2019　Revenue (IFRS) year on year +238.6%, Profit (loss) before tax (IFRS) as a share of revenue +257.7 points, Profit (loss) before tax (IFRS) loss to profit 2020　Profit (loss) before tax (IFRS) as a share of revenue +12.9 points 2021　Revenue (IFRS) year on year +100.3%, Profit (loss) before tax (IFRS) as a share of revenue -15.9 points 2022　Profit (loss) before tax (IFRS) as a share of revenue +4.5 points 2023　Profit (loss) before tax (IFRS) as a share of revenue -90.6 points, Profit (loss) before tax (IFRS) profit to loss 2024　Revenue (IFRS) year on year +125.9%, Profit (loss) before tax (IFRS) as a share of revenue +67.5 points 2025　Profit (loss) before tax (IFRS) as a share of revenue -34.3 points 30Latest value 2025 30¥ billion 30Highest in the period shown 2025 30¥ billion 2Lowest in the period shown 2013 2¥ billion ¥ billion

Recent performance trends

Year-on-year comparison

Period 2013 to 2025Disclosed

Item20212022202320242025
Revenue (IFRS) ¥17.7B ¥15.6B ¥12.8B ¥28.8B ¥29.6B
Year on year (%) +100.3%◆ -12.1% -18.0% +125.9%◆ +2.7%
Profit (loss) before tax (IFRS) ¥0.4B ¥1.1B -¥10.7B -¥4.7B -¥14.9B
Change from prior year -73.3% +149.0% profit to loss◆ 0.44x 3.21x
Profit (loss) before tax (IFRS) as a share of Revenue (IFRS) 2.4% 6.9% -83.7% -16.2% -50.5%
Change (percentage points) -15.9 points◆ +4.5 points◆ -90.6 points◆ +67.5 points◆ -34.3 points◆

Fiscal periods marked for changes

Earlier fiscal periods (7)
  • 2014Ordinary income (loss) as a share of revenue -11.2 points
  • 2015Revenue (IFRS) year on year +77.4%
  • 2017Revenue (IFRS) year on year -63.2%, Profit (loss) before tax (IFRS) as a share of revenue -119.3 points, Profit (loss) before tax (IFRS) profit to loss
  • 2019Revenue (IFRS) year on year +238.6%, Profit (loss) before tax (IFRS) as a share of revenue +257.7 points, Profit (loss) before tax (IFRS) loss to profit
  • 2020Profit (loss) before tax (IFRS) as a share of revenue +12.9 points
  • 2021Revenue (IFRS) year on year +100.3%, Profit (loss) before tax (IFRS) as a share of revenue -15.9 points
  • 2022Profit (loss) before tax (IFRS) as a share of revenue +4.5 points
  • 2023Profit (loss) before tax (IFRS) as a share of revenue -90.6 points, Profit (loss) before tax (IFRS) profit to loss
  • 2024Revenue (IFRS) year on year +125.9%, Profit (loss) before tax (IFRS) as a share of revenue +67.5 points
  • 2025Profit (loss) before tax (IFRS) as a share of revenue -34.3 points

Nxera Pharma

Earnings and net assets per share over time

Unit yenSource Annual securities reports

13 -38 -88 -139 4 years ago 3 years ago 2 years ago Last year This year Earnings per share yen 762 508 254 0 4 years ago 3 years ago 2 years ago Last year This year Net assets per share yen
Consolidated indicators (15 items)
Item4 years ago3 years ago2 years agoLast yearThis year
Revenue (IFRS) ¥17.7 billion ¥15.6 billion ¥12.8 billion ¥28.8 billion ¥29.6 billion
Profit (loss) before tax (IFRS) ¥0.4 billion ¥1.1 billion ¥-10.7 billion ¥-4.7 billion ¥-14.9 billion
Profit (loss) attributable to owners of parent (IFRS) ¥1.0 billion ¥0.4 billion ¥-7.2 billion ¥-4.8 billion ¥-12.5 billion
Comprehensive income attributable to owners of parent (IFRS) ¥5.6 billion ¥-0.3 billion ¥-1.1 billion ¥0.3 billion ¥-9.5 billion
Equity attributable to owners of parent (IFRS) ¥57.5 billion ¥57.9 billion ¥66.8 billion ¥68.5 billion ¥61.0 billion
Total assets (IFRS) ¥97.0 billion ¥99.4 billion ¥157.2 billion ¥151.5 billion ¥134.8 billion
Equity attributable to owners of parent per share (IFRS) 704.97 yen 707.2 yen 746.92 yen 762.15 yen 674.04 yen
Basic earnings (loss) per share (IFRS) 12.53 yen 4.68 yen -87.18 yen -53.92 yen -138.8 yen
Diluted earnings (loss) per share (IFRS) 12.4 yen 4.63 yen -87.18 yen -53.92 yen -138.8 yen
Ratio of equity attributable to owners of parent (IFRS) 59.3% 58.3% 42.5% 45.2% 45.3%
Return on equity attributable to owners of parent (IFRS) 1.9% 0.7% -11.5% -7.2% -19.3%
Net cash provided by (used in) operating activities (IFRS) ¥7.1 billion ¥10.0 billion ¥-5.3 billion ¥-7.7 billion ¥-2.7 billion
Net cash provided by (used in) investing activities (IFRS) ¥0.3 billion ¥1.0 billion ¥-63.8 billion ¥-4.8 billion ¥5.4 billion
Net cash provided by (used in) financing activities (IFRS) ¥11.1 billion ¥-4.9 billion ¥48.3 billion ¥-6.9 billion ¥-16.0 billion
Cash and cash equivalents (IFRS) ¥60.1 billion ¥66.6 billion ¥49.1 billion ¥32.3 billion ¥20.4 billion
Parent only indicators (12 items)
Item4 years ago3 years ago2 years agoLast yearThis year
Net sales ¥0.8 billion ¥1.1 billion ¥5.0 billion ¥6.6 billion ¥19.0 billion
Ordinary income (loss) ¥-4.7 billion ¥-1.6 billion ¥-3.3 billion ¥-1.5 billion ¥0.7 billion
Net income (loss) ¥-4.3 billion ¥-1.5 billion ¥-3.3 billion ¥2.1 billion ¥-23.7 billion
Capital stock ¥41.0 billion ¥41.3 billion ¥46.8 billion ¥47.2 billion ¥47.5 billion
Total number of issued shares (common stock) 81,518,316 shares 81,923,230 shares 89,446,777 shares 89,902,858 shares 90,496,735 shares
Net assets ¥58.5 billion ¥57.5 billion ¥65.2 billion ¥68.1 billion ¥44.9 billion
Total assets ¥94.3 billion ¥89.4 billion ¥142.0 billion ¥136.1 billion ¥105.0 billion
Net assets per share 714.03 yen 699.45 yen 726.29 yen 754.41 yen 493.98 yen
Basic earnings (loss) per share -52.47 yen -18.3 yen -39.81 yen 23.89 yen -262.41 yen
Diluted earnings per share Could not be retrieved Could not be retrieved Could not be retrieved 19.63 yen Could not be retrieved
Equity-to-asset ratio 61.7% 64.1% 45.7% 49.8% 42.6%
Return on equity Could not be retrieved Could not be retrieved Could not be retrieved 3.2% Could not be retrieved

Dividend history

Source: reporting company’s key figures, annual securities reports · 1 years (2015 to 2015)Parent-onlyDisclosed

0 periods Consecutive increases (own definition) through FY ending 3/2015
1 periods Consecutive periods with dividends (site definition) through FY ending 3/2015
No comparison with the previous year Dividend growth (year on year)
Fewer than six years Dividend growth (5-year annual rate)
Fiscal yearAnnual dividend per share Of which interimPayout ratio (as reported, parent only) Flag
FY ending 3/2015 ¥10 Could not be retrieved 59.0%

Shareholder composition

As of 2025-12-31Disclosed

Share ownership by holder category

23,161 Shareholders
22.37% Foreign holders (total) Industry median 9.03%
54.50% Individuals and others Industry median 55.96%

Nxera Pharma

Unit %Source Annual securities reports

  • Financial institutions11.32%
  • Securities firms5.79%
  • Other corporations6.00%
  • Foreign holders (institutions)22.11%
  • Foreign holders (individuals)0.26%
  • Individuals and others54.50%

Major shareholders

RankShareholderShareholding ratioShares held
1 日本マスタートラスト信託銀行株式会社(信託口) 9.43% 8,533,800
2 五味 大輔 8.03% 7,270,000
3 JICVGIオポチュニティファンド１号投資事業有限責任組合 6.2% 5,610,000
4 CLEARSTREAM BANKING S. A.（常任代理人 香港上海銀行東京支店） 3.37% 3,052,912
5 BROWN BROTHERS HARRIMAN(LUXEMBOURG) SCA CUSTODIANFOR ARCUS FUND SICAV - ARCUS JAPAN FUND（常任代理人 株式会社三菱UFJ銀行） 2.81% 2,542,800
6 ファイザー株式会社 2.08% 1,885,136
7 株式会社SBI証券 1.7% 1,537,549
8 MSIP CLIENT SECURITIES（常任代理人 モルガン・スタンレーMUFG証券株式会社） 1.5% 1,358,300
9 BOFAS INC OMNIBUS ACCOUNT（常任代理人 BofA証券株式会社） 1.34% 1,212,800
10 GOLDMAN SACHS INTERNATIONAL（常任代理人 ゴールドマン・サックス証券株式会社） 1.19% 1,079,956

Research and development expenses and capital expenditure

Source: R&D and capital expenditure sections, annual securities reports · 2 years (2020 to 2025)Disclosed

¥14.5 billion Research and development 48.8% of revenue (industry median 14.7%)
¥1.3 billion Capital expenditure 4.3% of revenue (industry median 5.0%)
Fiscal year Research and development Capital expenditure
FY ending 12/2025 ¥14.5 billion ¥1.3 billion
FY ending 12/2020 ¥3.8 billion Could not be retrieved

Revenue scale in the same industry

Nxera Pharma

Source Annual securities reports of each company

Pharmaceuticals: 68 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed

Workforce information

Source: Annual Securities Report (Jan 2025 to Dec 2025)Parent-onlyDisclosed

50 Employees (parent only) Industry median 94
46.8 Average age Industry median 44.3
3.7 years Average length of service Industry median 9.6 years
¥12.57 million Average annual salary Industry median ¥8.24 million
People and organisation
77.5¥ million Sales per employee Industry median 38.4¥ million FY ending 12/2025 · consolidated / calculated
¥-22.15 million Operating income per employee
61 Average temporary staff

Audit and disclosure information

Annual securities report, year ended 2025-12-31Disclosed

ItemValue
Audit firm EY新日本有限責任監査法人
Audit fees (this year, total) ¥78.00 million
Non-audit fees (this year, total) Not applicable
Audit fees (this year, network firms) ¥57.00 million
Going concern note Cannot be determined
Accounting standard IFRS

See the book series →

Sources and methodology

Retrieved disclosed figures

Accounts and values from the annual securities report, by section

Major management indicators (5 years) (25 items)

ItemValueConsolidated / Non-consolidated
Net cash provided by (used in) operating activities (IFRS) ¥-2.7 billion Consolidated
Basic earnings (loss) per share (IFRS) -138.8 yen Consolidated
Revenue (IFRS) ¥29.6 billion Consolidated
Diluted earnings (loss) per share (IFRS) -138.8 yen Consolidated
Profit (loss) attributable to owners of parent (IFRS) ¥-12.5 billion Consolidated
Comprehensive income attributable to owners of parent (IFRS) ¥-9.5 billion Consolidated
Net cash provided by (used in) investing activities (IFRS) ¥5.4 billion Consolidated
Cash and cash equivalents (IFRS) ¥20.4 billion Consolidated
Profit (loss) before tax (IFRS) ¥-14.9 billion Consolidated
Total assets (IFRS) ¥134.8 billion Consolidated
Equity attributable to owners of parent (IFRS) ¥61.0 billion Consolidated
Return on equity attributable to owners of parent (IFRS) -19.3% Consolidated
Ratio of equity attributable to owners of parent (IFRS) 45.3% Consolidated
Net cash provided by (used in) financing activities (IFRS) ¥-16.0 billion Consolidated
Equity attributable to owners of parent per share (IFRS) 674.04 yen Consolidated
Net sales ¥19.0 billion Parent only
Net income (loss) ¥-23.7 billion Parent only
Total number of issued shares (common stock) 90,496,735 shares Parent only
Net assets ¥44.9 billion Parent only
Ordinary income (loss) ¥0.7 billion Parent only
Total assets ¥105.0 billion Parent only
Equity-to-asset ratio 42.6% Parent only
Capital stock ¥47.5 billion Parent only
Basic earnings (loss) per share -262.41 yen Parent only
Net assets per share 493.98 yen Parent only

Employees (7 items)

ItemValueConsolidated / Non-consolidated
Number of employees 382 people Consolidated
Number of employees 382 people Consolidated
Average length of service (years) 3.7 years Parent only
Average annual salary ¥12.57 million Parent only
Average age (years) 46.8 years old Parent only
Number of employees 50 people Parent only
Number of employees 50 people Parent only

Other disclosed items (5 items)

ItemValueConsolidated / Non-consolidated
Average number of temporary employees 60.9 people Consolidated
Average number of temporary employees 60.9 people Consolidated
Average number of temporary employees 3.5 people Parent only
Average number of temporary employees 3.5 people Parent only
Total return on the share price index 188.9% Parent only

Shares (20 items)

ItemValueConsolidated / Non-consolidated
Number of shares held 34,083,253 shares Consolidated
Total number of shares held treasury shares etc 1,900 shares Consolidated
Number of issues whose number of shares decreased shares other than those not listed investment shares held for purposes other than pure investment largest holding company 1 issues Consolidated
Total sale amount for decreased shares shares other than those not listed investment shares held for purposes other than pure investment largest holding company ¥2.2 billion Consolidated
Number of shares 90,496,735 shares Consolidated
Shareholding ratio treasury shares etc 0.0% Consolidated
Shareholding ratio 37.7% Consolidated
Number of shares held in own name treasury shares etc 1,900 shares Consolidated
Total of valuation gain (loss) ¥-35.00 million Consolidated
Total of valuation gain (loss) ¥-0.1 billion Consolidated
Number of voting rights 904,371 units Consolidated
Carrying amount on the balance sheet ¥0.5 billion Consolidated
Carrying amount on the balance sheet ¥1.8 billion Consolidated
Book value equity securities not listed investment equity securities held for pure investment reporting company ¥32.00 million Consolidated
Book value equity securities other than those not listed investment equity securities held for pure investment largest holding company ¥48.00 million Consolidated
Number of issues 1 issues Consolidated
Number of issues 2 issues Consolidated
Number of issues 1 issues Consolidated
Number of issues 1 issues Consolidated
Total shareholder return 45.9% Parent only

Research and development (1 items)

ItemValueConsolidated / Non-consolidated
Research and development expenses ¥14.5 billion Consolidated

Property and facilities (1 items)

ItemValueConsolidated / Non-consolidated
Capital expenditures ¥1.3 billion Consolidated

Audit (4 items)

ItemValueConsolidated / Non-consolidated
Fees for audit and attestation services - reporting company ¥78.00 million Consolidated
Fees for audit and attestation services - total ¥57.00 million Consolidated
Fees for audit and attestation services - total ¥78.00 million Consolidated
Fees for audit and attestation services - consolidated subsidiaries ¥57.00 million Consolidated

Balance sheet (125 items)

ItemValueConsolidated / Non-consolidated
Other ¥-33.00 million Consolidated
Other ¥99.00 million Consolidated
Other ¥66.00 million Consolidated
Other current liabilities clifrs ¥3.1 billion Consolidated
Other current assets caifrs ¥2.3 billion Consolidated
Other components of equity IFRS ¥9.0 billion Consolidated
Other financial assets ¥2.9 billion Consolidated
Other non current liabilities nclifrs ¥3.1 billion Consolidated
Other non current assets ncaifrs ¥38.00 million Consolidated
Goodwill ¥26.6 billion Consolidated
Goodwill ¥-0.7 billion Consolidated
Goodwill IFRS ¥25.8 billion Consolidated
Goodwill IFRS ¥25.8 billion Consolidated
Lease obligations ¥0.9 billion Consolidated
Lease obligations ¥3.5 billion Consolidated
Work in process ¥2.5 billion Consolidated
In-process research and development ¥0.2 billion Consolidated
In process research and development IFRS ¥0.2 billion Consolidated
Borrowings ¥21.1 billion Consolidated
Retained earnings IFRS ¥-17.5 billion Consolidated
Raw materials ¥8.5 billion Consolidated
Trade and other payables clifrs ¥7.5 billion Consolidated
Trade and other receivables caifrs ¥7.7 billion Consolidated
Tools, furniture and fixtures ¥1.0 billion Consolidated
Tools, furniture and fixtures ¥-0.5 billion Consolidated
Tools, furniture and fixtures ¥0.4 billion Consolidated
Buildings and structures ¥3.3 billion Consolidated
Buildings and structures ¥-1.4 billion Consolidated
Buildings and structures IFRS ¥1.9 billion Consolidated
Construction in progress ¥17.00 million Consolidated
Construction in progress IFRS ¥17.00 million Consolidated
Provisions nclifrs ¥0.5 billion Consolidated
Technical assets ¥-10.8 billion Consolidated
Technical assets ¥18.3 billion Consolidated
Technology based intangible assets IFRS ¥7.5 billion Consolidated
Property, plant and equipment ¥14.2 billion Consolidated
Property, plant and equipment ¥-6.7 billion Consolidated
Property plant and equipment IFRS ¥7.5 billion Consolidated
Property plant and equipment IFRS ¥7.5 billion Consolidated
Income taxes receivable ¥2.7 billion Consolidated
Income taxes payable ¥0.2 billion Consolidated
Inventories ¥11.3 billion Consolidated
Inventories ¥11.3 billion Consolidated
Machinery, equipment ¥2.8 billion Consolidated
Machinery, equipment ¥-1.9 billion Consolidated
Machinery and equipment IFRS ¥0.9 billion Consolidated
Total current liabilities IFRS ¥17.5 billion Consolidated
Current assets IFRS ¥44.5 billion Consolidated
Intangible assets accumulated amortization and impairment losses IFRS ¥-21.9 billion Consolidated
Intangible assets acquisition cost IFRS ¥71.2 billion Consolidated
Intangible assets IFRS ¥49.2 billion Consolidated
Intangible assets IFRS ¥49.2 billion Consolidated
Cash and cash equivalents (IFRS) ¥20.4 billion Consolidated
Cash and cash equivalents (IFRS) ¥20.4 billion Consolidated
Bonds payable ¥26.1 billion Consolidated
Net assets ¥61.0 billion Consolidated
Net assets ¥61.0 billion Consolidated
Total assets ¥134.8 billion Consolidated
Deferred tax liabilities IFRS ¥0 Consolidated
Deferred tax assets IFRS ¥4.9 billion Consolidated
Treasury shares IFRS ¥-3.00 million Consolidated
Finished goods ¥0.3 billion Consolidated
Intangible assets associated with products accumulated amortization and impairment losses IFRS ¥-4.7 billion Consolidated
Intangible assets associated with products acquisition cost IFRS ¥46.0 billion Consolidated
Intangible assets associated with products IFRS ¥41.3 billion Consolidated
Equity attributable to owners of parent (IFRS) ¥61.0 billion Consolidated
Liabilities and equity IFRS ¥134.8 billion Consolidated
Liabilities IFRS ¥73.8 billion Consolidated
Capital surplus IFRS ¥22.1 billion Consolidated
Share capital IFRS ¥47.5 billion Consolidated
Non current labilities IFRS ¥56.3 billion Consolidated
Non current assets IFRS ¥90.3 billion Consolidated
Customer relationship ¥-6.4 billion Consolidated
Customer relationship ¥6.6 billion Consolidated
Customer related assets IFRS ¥0.2 billion Consolidated
Current portion of long term borrowings clifrs ¥5.8 billion Consolidated
Other ¥51.00 million Parent only
Other ¥0.2 billion Parent only
Other capital surplus ¥20.7 billion Parent only
Software ¥8.00 million Parent only
Work in process ¥0.4 billion Parent only
Investments in capital ¥32.00 million Parent only
Retained earnings ¥-23.7 billion Parent only
Prepaid expenses ¥0.3 billion Parent only
Raw materials ¥8.5 billion Parent only
Merchandise ¥0.6 billion Parent only
Non-current liabilities ¥49.0 billion Parent only
Non-current assets ¥87.6 billion Parent only
Tools, furniture and fixtures ¥13.00 million Parent only
Buildings, net ¥1.00 million Parent only
Investments and other assets ¥46.3 billion Parent only
Subscription rights to shares ¥0.2 billion Parent only
Bonds with subscription rights to shares ¥27.4 billion Parent only
Property, plant and equipment ¥14.00 million Parent only
Consumption taxes receivable ¥0.4 billion Parent only
Income taxes payable ¥87.00 million Parent only
Accrued expenses ¥0.1 billion Parent only
Accounts payable - other ¥1.6 billion Parent only
Shareholders' equity ¥44.7 billion Parent only
Stock-based compensation allowance-NCL ¥0.4 billion Parent only
Provision for share-based compensation ¥0.4 billion Parent only
Inventories ¥9.5 billion Parent only
Current liabilities ¥11.0 billion Parent only
Current assets ¥17.4 billion Parent only
Intangible assets ¥41.2 billion Parent only
Cash and deposits ¥5.5 billion Parent only
Net assets ¥44.9 billion Parent only
Net assets ¥44.9 billion Parent only
Total assets ¥105.0 billion Parent only
Retained earnings brought forward ¥-23.7 billion Parent only
Treasury stock ¥-3.00 million Parent only
Liabilities ¥60.0 billion Parent only
Liabilities and net assets ¥105.0 billion Parent only
Accounts payable - trade ¥2.6 billion Parent only
Capital surplus ¥20.9 billion Parent only
Legal capital surplus ¥0.3 billion Parent only
Capital stock ¥47.5 billion Parent only
Provision for bonuses ¥0.2 billion Parent only
Long-term loans payable ¥21.1 billion Parent only
Accounts receivable from subsidiaries and affiliates trade ¥1.1 billion Parent only
Accounts receivable from subsidiaries and associates-other ¥0.2 billion Parent only
Shares of subsidiaries and associates ¥28.8 billion Parent only
Long-term loans receivable from subsidiaries and affiliates ¥17.5 billion Parent only
Deposits received ¥66.00 million Parent only
Current portion of long-term loans payable ¥5.8 billion Parent only

Accounts unique to this company (24 items)

ItemValueConsolidated / Non-consolidated
Revenue ¥1.9 billion Consolidated
Revenue ¥-10.00 million Consolidated
Revenue ¥1.9 billion Consolidated
Revenue ¥4.6 billion Consolidated
Revenue ¥-1.6 billion Consolidated
Revenue ¥-1.9 billion Consolidated
Revenue ¥-4.5 billion Consolidated
Revenue ¥7.0 billion Consolidated
Revenue ¥12.00 million Consolidated
Revenue ¥64.00 million Consolidated
Revenue ¥-2.9 billion Consolidated
Revenue ¥-6.00 million Consolidated
Revenue ¥-1.00 million Consolidated
Revenue ¥4.1 billion Consolidated
Revenue ¥6.00 million Consolidated
Revenue ¥63.00 million Consolidated
Revenue ¥27.00 million Consolidated
Revenue ¥14.00 million Consolidated
Revenue ¥41.2 billion Parent only
Revenue ¥65.00 million Parent only
Revenue ¥2.8 billion Parent only
Revenue ¥0.2 billion Parent only
Revenue ¥4.8 billion Parent only
Revenue ¥54.00 million Parent only

Statement of income (83 items)

ItemValueConsolidated / Non-consolidated
Other ¥42.00 million Consolidated
Other ¥36.00 million Consolidated
Other ¥2.7 billion Consolidated
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss ociifrs ¥0.2 billion Consolidated
Other comprehensive income IFRS ¥3.1 billion Consolidated
Other comprehensive income IFRS ¥3.1 billion Consolidated
Other income IFRS ¥1.7 billion Consolidated
Other income IFRS ¥1.7 billion Consolidated
Other expenses IFRS ¥1.8 billion Consolidated
Other expenses IFRS ¥1.8 billion Consolidated
Lease obligations ¥0.1 billion Consolidated
Personnel expenses ¥6.2 billion Consolidated
Financial liabilities measured at amortized cost ¥0.7 billion Consolidated
Interest income IFRS ¥1.0 billion Consolidated
Operating income ¥-8.5 billion Consolidated
Net cash provided by (used in) operating activities ¥-2.7 billion Consolidated
Loss on retirement of fixed assets IFRS ¥63.00 million Consolidated
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss ociifrs ¥2.9 billion Consolidated
Basic earnings loss per share IFRS -138.8 yen Consolidated
Cost of sales IFRS ¥8.2 billion Consolidated
Gross profit IFRS ¥21.4 billion Consolidated
Net sales ¥29.6 billion Consolidated
Diluted earnings loss per share IFRS -138.8 yen Consolidated
Research and development expenditure recognized as expense during period IFRS ¥14.5 billion Consolidated
Profit loss IFRS ¥-12.5 billion Consolidated
Profit loss IFRS ¥-12.5 billion Consolidated
Profit loss IFRS ¥-12.5 billion Consolidated
Comprehensive income (IFRS) ¥-9.5 billion Consolidated
Comprehensive income (IFRS) ¥-9.5 billion Consolidated
Comprehensive income (IFRS) ¥-9.5 billion Consolidated
Net income ¥-12.5 billion Consolidated
Total transactions with owners IFRS ¥1.9 billion Consolidated
Net cash provided by (used in) investing activities (IFRS) ¥5.4 billion Consolidated
Share-based payment transactions ¥2.0 billion Consolidated
Business consignment expenses ¥2.5 billion Consolidated
Income tax expense IFRS ¥-2.4 billion Consolidated
Depreciation ¥3.5 billion Consolidated
Foreign exchange gain IFRS ¥16.00 million Consolidated
Net increase decrease in cash and cash equivalents IFRS ¥-11.9 billion Consolidated
Effect of exchange rate changes on cash and cash equivalents IFRS ¥1.4 billion Consolidated
Total of items that will not be reclassified to profit or loss ociifrs ¥0.2 billion Consolidated
Total of items that may be reclassified to profit or loss ociifrs ¥2.9 billion Consolidated
Profit loss before tax IFRS ¥-14.9 billion Consolidated
Profit loss before tax IFRS ¥-14.9 billion Consolidated
Purchase of treasury stock ¥-0 Consolidated
Government grant income IFRS ¥1.6 billion Consolidated
Comprehensive income attributable to owners of parent IFRS ¥-9.5 billion Consolidated
Net cash provided by (used in) financing activities (IFRS) ¥-16.0 billion Consolidated
Sales promotion expenses IFRS ¥0.4 billion Consolidated
Selling general and administrative expenses IFRS ¥15.2 billion Consolidated
Selling general and administrative expenses IFRS ¥15.2 billion Consolidated
Finance income IFRS ¥1.0 billion Consolidated
Finance income IFRS ¥1.0 billion Consolidated
Finance costs IFRS ¥7.5 billion Consolidated
Finance costs IFRS ¥7.5 billion Consolidated
General and administrative expenses ¥9.6 billion Parent only
Personnel expenses ¥3.2 billion Parent only
Interest income ¥0.3 billion Parent only
Operating income ¥2.6 billion Parent only
Non-operating income ¥3.3 billion Parent only
Non-operating expenses ¥5.2 billion Parent only
Cost of sales ¥6.8 billion Parent only
Gross profit (loss) ¥12.2 billion Parent only
Net sales ¥19.0 billion Parent only
Net income (loss) ¥-23.7 billion Parent only
Net income (loss) ¥-23.7 billion Parent only
Interest expenses ¥0.3 billion Parent only
Commission fees ¥14.00 million Parent only
Issuance of new shares ¥0.6 billion Parent only
Gain on reversal of share acquisition rights ¥1.00 million Parent only
Business consignment expenses ¥2.9 billion Parent only
Income taxes - current ¥15.00 million Parent only
Income taxes ¥15.00 million Parent only
Depreciation ¥1.8 billion Parent only
Foreign exchange gains ¥45.00 million Parent only
Extraordinary income ¥1.00 million Parent only
Extraordinary loss ¥24.4 billion Parent only
Income (loss) before income taxes ¥-23.7 billion Parent only
Ordinary income ¥0.7 billion Parent only
Purchase of treasury stock ¥-0 Parent only
Loss on valuation of shares of subsidiaries and associates ¥24.3 billion Parent only
Miscellaneous income ¥0 Parent only
Other ¥41.00 million Parent only

Statement of cash flows (24 items)

ItemValueConsolidated / Non-consolidated
Other ¥28.00 million Consolidated
Other ¥-0 Consolidated
Other ¥0.9 billion Consolidated
Repayments of lease obligations ¥-0.9 billion Consolidated
Interest paid ope cfifrs ¥-0.5 billion Consolidated
Interest and dividends received ope cfifrs ¥1.1 billion Consolidated
Interest income ¥-1.0 billion Consolidated
Increase (decrease) in trade and other payables ¥3.0 billion Consolidated
Decrease (increase) in trade and other receivables ¥-1.0 billion Consolidated
Net decrease increase in time deposits inv cfifrs ¥3.9 billion Consolidated
Subtotal ¥-4.2 billion Consolidated
Proceeds from sale of investment securities inv cfifrs ¥2.1 billion Consolidated
Interest expenses ¥0.9 billion Consolidated
Purchase of property plant and equipment inv cfifrs ¥-0.4 billion Consolidated
Share-based payment expenses ¥2.0 billion Consolidated
Decrease (increase) in inventories ¥-2.5 billion Consolidated
Income taxes paid ope cfifrs ¥-0.2 billion Consolidated
Income taxes refund ope cfifrs ¥1.2 billion Consolidated
Depreciation and amortization ¥4.4 billion Consolidated
Impairment losses reversal of impairment losses ope cfifrs ¥1.2 billion Consolidated
Foreign exchange loss (gain) ¥-70.00 million Consolidated
Purchase of intangible assets inv cfifrs ¥-0.2 billion Consolidated
Redemption of bonds fin cfifrs ¥-4.8 billion Consolidated
Repayments of long term borrowings fin cfifrs ¥-5.8 billion Consolidated

Statement of changes in equity (2 items)

ItemValueConsolidated / Non-consolidated
Total changes during the period ¥-23.1 billion Parent only
Net changes in items other than shareholders' equity ¥14.00 million Parent only
Basic indicators
ItemValueConsolidated / Non-consolidatedSource
Net cash provided by (used in) operating activities ¥-2.7 billion ConsolidatedDisclosed
Number of employees 382 ConsolidatedDisclosed
Net assets ¥61.0 billion ConsolidatedDisclosed
Net sales ¥29.6 billion ConsolidatedDisclosed
Operating income ¥-8.5 billion ConsolidatedDisclosed
Ordinary income ¥0.7 billion Parent onlyDisclosed
Net income ¥-12.5 billion ConsolidatedDisclosed
Total assets ¥134.8 billion ConsolidatedDisclosed
Operating margin -28.6%ConsolidatedCalculated
Net margin -42.3%ConsolidatedCalculated
Sales per employee 77526178 yenConsolidatedCalculated
Total asset turnover 0.22 timesConsolidatedCalculated
Net assets to total assets 45.3%ConsolidatedCalculated
How to read the figures, and caveats

Terms

  • Consolidated: the parent company together with the subsidiaries it consolidates
  • Parent-only: the single company that filed the annual securities report
  • Calculated: a disclosed figure put through the formula shown
  • Not disclosed: no such value in the filing (not treated as zero)
  • Not retrieved: a value this page could not extract, including values in the filing that could not be matched. The same item may appear in another table
  • Segment: a business division the company uses in its disclosures
  • Industry median: the middle value among companies in the same industry that disclose the item
  • ★: position when every company is lined up by value (not a judgement of the company)See the formulas
  • Source: document name, period covered, filing date and where it was obtained
  • Tables scroll sideways

Key figures

  • Operating margin -28.6%　Operating income ÷ net sales 　＝ ¥-8.5 billion ÷ ¥29.6 billion
    Operating income ÷ net sales. The denominator is Net sales (Consolidated, IFRS).
  • Net margin -42.3%　Net income ÷ net sales 　＝ ¥-12.5 billion ÷ ¥29.6 billion
    Net income ÷ net sales. The denominator is Net sales (Consolidated, IFRS).
  • Sales per employee 77,526,178 yen　Sales or operating revenue ÷ employees 　＝ ¥29.6 billion ÷ 382 people
    Sales or operating revenue ÷ employees. The denominator is Number of employees (Consolidated, Japanese GAAP).
  • Total asset turnover 0.22 times　Sales or operating revenue ÷ total assets 　＝ ¥29.6 billion ÷ ¥134.8 billion
    Sales or operating revenue ÷ total assets. The denominator is Total assets (Consolidated, IFRS).
  • Net assets to total assets 45.3%　Net assets ÷ total assets 　＝ ¥61.0 billion ÷ ¥134.8 billion
    Net assets ÷ total assets. The denominator is Total assets (Consolidated, IFRS).

Company details

  • Representative　President and Representative Executive Officer, gBizINFO

Amounts by account

  • Totals and their component lines together; consolidated and parent-only figures mixed (right-hand column)

Selling, general and administrative expenses

  • Breakdown of selling, general and administrative expenses (costs of selling and running the company). Cost of sales not included
  • Each item: already inside the SG&A total (not added to it)

Finance

  • Net assets to total assets　Net assets ÷ total assets
  • Return on assets (ROA)　Net income ÷ total assets (consolidated)
  • Net assets per share　Parent only
  • Free cash flow　Free cash flow: operating cash flow (cash generated by the business) plus investing cash flow (asset purchases, disposals and other investments), consolidated
  • Total assets　Consolidated
  • Goodwill (the part of the acquisition price above the net assets acquired)　42% of net assets (consolidated)

Capital allocation

  • ★: position when all companies are sorted by value and cut into fifths (a position, not a rating). The five items with ★: only where both numerator and denominator are available on a consolidated basisSee the formulas
  • Increase in working capital　(increase in trade receivables + increase in inventories) ÷ net sales (or operating revenue)。Trade receivables up ¥1.0 billion + inventories up ¥2.5 billion, over net sales ¥29.6 billion
  • Property, plant and equipment purchases relative to depreciation　Purchase of property, plant and equipment ÷ depreciation。Purchase of property, plant and equipment ¥0.4 billion, over depreciation ¥4.4 billion

Long-term changes in performance

  • Revenue　Disclosed value for 2025 ÷ disclosed value for 2013

Year-on-year comparison

  • Year on year: calculated only where the item, reporting range and accounting standard match and the periods are consecutive
  • Comparison basis not confirmed: periods with a change of accounting standard or reporting range, a moved fiscal year end, or an unconfirmed period
  • ◆: a period where revenue moved 20% or more from the prior year, profit as a share of revenue moved 2.0 percentage points or more, or profit or loss changed sign. Item used named in the table and list. Not a ranking of companies

Earnings and net assets per share over time

  • Earnings per share = net profit ÷ shares; net assets per share = net assets ÷ shares. Disclosed values from the key financial indicators of the annual securities report. No share prices used

Dividend history

  • Payout ratio: dividends as a proportion of net profit. Dividend amounts and payout ratios: the reporting company’s parent-only disclosed values (as written in the annual securities report, not recalculated from consolidated profit). Consecutive increases: years in a row, from the latest backwards, in which the annual dividend per share rose. Consecutive years with a dividend: years in a row with an annual dividend per share above zero. Both this site’s own count (not the criteria of any published index). A year with no disclosure not read as zero; counting stops there. Range limited to the years listed above.

Share ownership by holder category

  • Source: ownership table, annual securities report. Percentages as disclosed, calculated on trading units (some companies do not total exactly 100%). Foreign holders (total): institutions and individuals combined. “Individuals and others”: a register category (not necessarily the share actually held by individuals). Industry median: the middle value among companies in Pharmaceuticals that disclose the item (industries with at least 5 companies only).

Major shareholders

  • Source: major shareholders table, annual securities report. Trust bank holdings as written (whose trust is not disclosed)

Research and development expenses and capital expenditure

  • Research and development: total in the R&D section of the annual securities report. Capital expenditure: this year’s actual spending in the capital expenditure overview (not a plan). Years: only those available in the annual securities reports on hand (one to four per company); no row for other years. Share of revenue: divided by consolidated revenue in the same annual securities report. Industry median: the middle value among companies in Pharmaceuticals that disclose the item (industries with at least 5 companies only).

Revenue scale in the same industry

  • Revenue (disclosed values) of companies in the same industry, using the same grouping as the industry pages. Only the top three and the two companies either side of this one. Bar length relative to the largest company (100). An order of size, not a ranking of quality

Workforce information

  • All four: the reporting company (parent-only), as disclosed in the employee section of the annual securities report. Employees across the consolidated group: 382 (a different scope, kept apart from the four above). Industry median: the middle value among companies in Pharmaceuticals that disclose the item (industries with at least 5 companies only).

People and organisation

  • Sales per employee　Net sales (or operating revenue) ÷ employees
  • Operating income per employee　Operating income ÷ employees
  • Average temporary staff　Consolidated, average headcount other than regular employees

Audit and disclosure information

  • Whether there is a going concern note (the accounting assumption that a company will continue operating), and audit information
  • Audit firm, audit fees, going concern note and accounting standard: facts written in the latest annual securities report and the audit report filed with it (not a judgement of the company). Going concern note: “note” when the note text is present, “not applicable” when the report states nothing to report, “cannot be determined” when neither appears. Note text not reproduced. Amended filings not shown (annual securities reports only)

Data sources and calculation methods

Primary source: the annual securities report of Nxera Pharma Co., Ltd. on EDINET, the FSA’s disclosure system (free to read)
Corporate number: 4010001021288 / Accounting standard: IFRS

  • Amounts: machine transcription of EDINET XBRL (no manual re-keying). Long narrative notes are text and not in the account list. Identifiers: machine transcription of the EDINET code list (retrieved 2026-08-22)
  • ★: position of the value calculated from disclosed figures among the 4,240 companies on this site, on a five-step scale. Not a judgement of the company. No forecasts usedThe formulas and how they are counted
  • No rank: net assets as a share of total assets, cash conversion and revenue per employee (size alone does not show quality). Industry median shown for comparison. Cash conversion of 100%: operating cash flow equal to operating profit
  • Profit-and-loss chart: only where “sales − cost of sales − SG&A = operating income” holds between disclosed values. Cost breakdown: the six largest SG&A items
  • Trend charts: key financial indicators of the annual securities report. Amounts in billions of yen (dividend per share in yen). Long-run chart joins reports filed in different years (newer report for overlapping years). Some items stop part-way after a change of accounting standard. A stock split changes the weight of one share. Consolidated and parent-only in separate tables
  • Revenue scale in the same industry: bars of revenue (disclosed values) of companies in the same industry grouping as the industry pages, largest first. Only the top three and the two companies either side of this one. Each company’s latest fiscal year. An order of size, not a ranking of quality or an investment view
  • Share prices: not published (no data source allows redistribution). No share-price-based indicators (such as the price earnings ratio) and no extension of past growth into the future
  • Average age, average length of service and average annual salary: the reporting company alone (the parent). At a holding company, a small head-office staff. Payout ratio (basic facts): dividend per share ÷ consolidated earnings per share, calculated here (the payout ratio in the annual securities report is the reporting company’s figure, on a different basis). Representative and founding date: gBizINFO (Ministry of Economy, Trade and Industry), some companies only
  • “Retrieved disclosed figures”: every value readable as a number from the annual securities report. Company-wide values only (no segment or other breakdowns)
  • Segment table: machine transcription of the segment information in the annual securities report. Business names as labelled by the company in its XBRL. No table where segment sales differ from the disclosed total by more than 1%. Adjustments, corporate, eliminations and “other” left out of the table and the share denominator, as they are not businesses
  • Breakdowns of amounts, not diagrams of how the business works. Who pays whom, and for what, is not in the disclosed figures; no lines drawn from guesswork